Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. plans to publicly transfer 100% equity of its wholly-owned subsidiary, Zhejiang Pharmaceutical Industry Co., Ltd., to optimize its business structure and focus on core pharmaceutical industrial advantages, with a proposed base price of 430 million yuan [1][2]. Transaction Overview - The transaction aims to enhance overall profit margins and resource allocation efficiency by divesting a non-core business segment [2]. - The assessed value of the subsidiary's 100% equity is 392.2339 million yuan, with a proposed public listing base price of 430 million yuan [2][8]. - The transaction will be conducted through a public listing, and the specific buyer has not yet been determined [2][9]. Financial Information - As of May 31, 2025, the subsidiary's total assets were 2.05213 billion yuan, total liabilities were 1.6995496 billion yuan, and net assets were 352.5808 million yuan [7]. - The subsidiary reported operating income of 1.6888918 billion yuan and a net profit of 19.5205 million yuan for the year [7][8]. Valuation and Pricing - The valuation was conducted using the asset-based approach, resulting in a shareholder equity value of 392.2339 million yuan, with an 11.25% increase in value [8]. - The pricing strategy is based on the assessed value and will be finalized through the public listing process [8]. Impact on Company - The divestiture of the subsidiary is expected to streamline the company's operations, allowing it to focus on complex formulations and synthetic biology sectors, which are its strategic priorities [9][10]. - The company anticipates a reduction in consolidated revenue by over 3 billion yuan annually due to the sale, but expects an improvement in profit margins in its core pharmaceutical business [10].

《企业会计准则第 22 号 证券代码：600267 证券简称：海正药业 公告编号：临 2025-44 号 浙江海正药业股份有限公司 关于计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日召开 第十届董事会第六次会议和第十届监事会第三次会议，审议通过了《关于计提资 产减值准备的议案》，为了更加客观、公正地反映公司财务状况和资产价值，根 据《企业会计准则》等相关规定，结合企业实际经营情况和资产现状，本着谨慎 性原则，对 2025 年半年度各项资产进行了减值迹象的识别和测试，并根据测试 结果对其中存在减值迹象的资产相应计提资产减值准备，现将具体情况公告如 下： 一、本次计提资产减值准备情况概述 公司根据依照《企业会计准则第 8 号——资产减值》 ——金融工具确认和计量》等相关规定以及公司的实际业务情况，对公司 2025 年半年度合并范围内相关资产进行减值测试，根据测试结果，公司部分资产存在 减值的情形，计提各项资产减值损失 14,24 ...

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has corrected accounting errors in its financial statements for the years 2021, 2022, and 2023, which has impacted its reported revenues, costs, and profits [1]. Financial Summary 2021 Financial Statements - The corrected consolidated income statement for 2021 shows total operating revenue of RMB 11,572,039,167.66, an increase from RMB 11,354,395,743.16 in the previous year [1]. - Total operating costs were adjusted to RMB 10,932,530,923.39 from RMB 10,761,672,748.74, with operating costs specifically rising to RMB 6,626,576,550.00 from RMB 6,441,029,671.47 [1]. - The net profit for 2021 was revised to RMB 510,919,446.93, down from RMB 723,167,293.93 [1]. Cash Flow Analysis - The net cash flow from operating activities for 2021 was RMB 1,758,968,465.90, an increase from RMB 1,589,608,756.67 in the previous year [2]. - Cash inflows from operating activities totaled RMB 12,078,955,666.31, while cash outflows were RMB 10,319,987,200.41 [2]. - The net cash flow from investing activities was negative at RMB -515,727,836.37, compared to a positive RMB 1,007,747,830.32 in the previous year [2]. - The net cash flow from financing activities was negative at RMB -2,074,013,122.31, down from RMB -2,229,211,579.89 [3]. 2022 Financial Statements - The corrected consolidated income statement for 2022 indicates total operating revenue of RMB 11,379,008,474.81, a decrease from RMB 11,572,039,167.66 in 2021 [9]. - Total operating costs for 2022 were RMB 10,603,997,297.39, down from RMB 10,932,530,923.39 in 2021 [9]. - The net profit for 2022 was reported at RMB 491,234,445.41, a decrease from RMB 510,919,446.93 in 2021 [9]. Key Financial Ratios - The weighted average return on equity for the reporting period was 7.49% [8]. - Basic earnings per share were reported at 0.43, while diluted earnings per share were also 0.43 [9].

浙江海正药业股份有限公司募集资金管理办法 浙江海正药业股份有限公司 募集资金管理办法 第一章 总则 第一条 为了规范本公司募集资金的使用与管理，提高募集资金使用效益，保护 投资者的合法权益，根据《公司法》 《证券法》 《首次公开发行股票注册管理办法》 《上 市公司证券发行注册管理办法》 《上市公司募集资金监管规则》 《上海证券交易所股票 上市规则》及《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等相关 法律法规，制定本办法。 第二条 本办法适用于公司通过发行股票或者其他具有股权性质的证券，向投资 者募集并用于特定用途的资金监管，但不包括上市公司为实施股权激励计划募集的资 金监管。 本办法所称超募资金是指实际募集资金净额超过计划募集资金金额的部分。 第三条 公司募集资金应当专款专用。募集资金只能用于公司对外披露的募集资 金投资项目（以下简称"募投项目"），公司负责制定详细的募集资金使用计划。募集 资金的管理应遵循规范、安全、高效、透明的原则。 《监管规则适用指引——上市类第 1 号》对上市公司发行股份、可转换公司债券 购买资产并募集配套资金用途另有规定的，从其规定。 第四条 募投项目通过公司的子公 ...

General Principles - The purpose of the related party transaction system is to standardize transactions between Zhejiang Haizheng Pharmaceutical Co., Ltd. and its related parties, ensuring fairness, justice, and transparency while protecting the legal rights of the company and all shareholders [2][3] Definition of Related Parties - Related parties include both legal entities and natural persons that have a special relationship with the company, such as those who directly or indirectly control the company or hold more than 5% of its shares [2][3][4] Related Transactions - Related transactions refer to the transfer of resources or obligations between the company and its related parties, including asset purchases, investments, and other agreements that may lead to resource transfer [5][6] Decision-Making Procedures for Related Transactions - Transactions involving guarantees for related parties require approval from a majority of non-related directors and must be submitted for shareholder meeting approval [9][10] - Transactions exceeding certain thresholds (e.g., 300,000 yuan for natural persons and 3 million yuan for legal entities) must be disclosed and approved by independent directors [10][11] Exemptions from Approval - Certain transactions, such as those where the company receives benefits without obligations or where the interest rates are at market levels, may be exempt from the approval process [12][13] Avoidance Measures - Related directors must abstain from voting on related transactions, and the board meeting can proceed with a majority of non-related directors present [18][19] Information Disclosure - The company is required to disclose details of related transactions, including the nature of the relationship, transaction terms, and pricing basis, in accordance with the regulations of the Shanghai Stock Exchange [20][21]

Core Points - The compensation management system for directors and senior management at Zhejiang Haizheng Pharmaceutical Co., Ltd. aims to enhance work motivation and improve management levels, aligning with modern corporate governance and legal regulations [1][2] - The system applies to independent directors, internal directors, external directors, and senior management personnel, including the president, senior vice presidents, CFO, and board secretary [1][2] Compensation Principles - Compensation is linked to job value and responsibilities, ensuring competitiveness with market standards [2] - Compensation is tied to company performance and individual achievements, promoting shared outcomes and responsibilities [2] - The system emphasizes fairness, transparency, and scientific assessment in compensation distribution [2] Compensation Management Structure - The shareholders' meeting is responsible for reviewing director compensation, while the board of directors oversees senior management compensation [2] - The compensation and assessment committee of the board formulates assessment standards and compensation policies for directors and senior management [2][3] Compensation Standards - Independent directors' remuneration is based on their risk responsibilities and market levels, determined annually [3] - Internal directors do not receive separate director allowances; their compensation follows the senior management compensation system [3] - External directors do not receive compensation from the company [3] - Senior management operates on a salary system comprising a base salary and performance-based salary, linked to annual performance contracts [3][4] Compensation Distribution - Compensation for non-independent directors and senior management is distributed according to their positions [4] - Independent director allowances are paid quarterly, and all compensation is pre-tax [4] Compensation Adjustment - The compensation system is designed to adapt to the company's strategic needs and operational changes [5] - Adjustments are based on industry salary levels, inflation, company profitability, organizational changes, and individual role changes [5] Special Provisions - The board may establish temporary rewards or penalties for non-independent directors and senior management within the annual budget [5] Implementation - The compensation management system is effective upon approval by the shareholders' meeting and will be revised as necessary [5]

浙江海正药业股份有限公司董事会薪酬与考核委员会实施细则 浙江海正药业股份有限公司 股东会议事规则 第一章 总则 第一条 为规范浙江海正药业股份有限公司（以下简称"公司"）行为，保 证股东会依法行使职权，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、 《中华人民共和国证券法》 （以下简称"《证券法》"）、 《浙江海正药业股份有限公 司章程》（以下简称"《公司章程》"）的规定，制定本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、行政法规、本规则及《公司章程》的相 关规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第四条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第五条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的 6 个月内举行。临时股东会不定期召开，出现《公 司法》及《公司章程》规定的应当召开临时股东会的情形时，临时股东会应当在 两个月内召开。 公司在上述期限内不能召开股东会的， ...

浙江海正药业股份有限公司董事会议事规则 浙江海正药业股份有限公司 董事会议事规则 第一条 宗旨 为了进一步规范浙江海正药业股份有限公司（以下简称"公司"或"本公司"） 董事会的议事方式和决策程序，促使董事和董事会有效地履行其职责，提高董事会规 范运作和科学决策水平，根据《中华人民共和国公司法》 《中华人民共和国证券法》 《上 市公司治理准则》 《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监 管指引第 1 号——规范运作》及《浙江海正药业股份有限公司公司章程》（以下简称 "《公司章程》"）等有关规定，并结合本公司实际情况，特制订本规则。 公司设董事会，对股东会负责。董事会制定董事会议事规则，以确保董事会落实 股东会决议，提高工作效率，保证科学决策。 第二条 董事会日常事务处理 董事会下设证券管理部，处理董事会日常事务。 董事会秘书管理证券管理部，并保管董事会印章。 第三条 定期会议 董事会会议分为定期会议和临时会议。 董事会每年应当至少在上下两个半年度各召开一次定期会议。 第四条 定期会议的提案 在发出召开董事会定期会议的通知前，证券管理部应当充分征求各董事的意见， 证券管理部在收到上述书面提议 ...

Core Points - The articles outline the regulations and governance structure of Zhejiang Hisun Pharmaceutical Co., Ltd, emphasizing the protection of the rights of shareholders, employees, and creditors [1][3][4] - The company is established as a publicly listed joint-stock company with a registered capital of RMB 1,198.848196 million [2][7] - The company aims to be a leading pharmaceutical enterprise focusing on research and innovation, adhering to high production standards [5][6] Group 1: General Provisions - The company is established under the Company Law and other relevant regulations, with its legal representative being the chairman elected by the board [1][2] - The company has a permanent existence as a publicly listed joint-stock company [2] - The articles serve as a legally binding document governing the relationships and rights among the company, shareholders, and management [3][4] Group 2: Business Objectives and Scope - The company's business objective is to provide high-quality pharmaceutical products and health solutions globally, driven by research and innovation [5] - The business scope includes drug production, pharmaceutical wholesale, and various related activities, subject to legal approvals [5][6] Group 3: Shares - The company issues shares in the form of stocks, ensuring equal rights for all shares of the same category [7][8] - The total number of issued shares is 1,198,481,196, all of which are ordinary shares [7][8] - The company can provide financial assistance for acquiring its shares under specific conditions approved by the board [8][9] Group 4: Shareholder Rights and Meetings - Shareholders have rights to dividends, voting, and participation in company decisions, with equal rights for shares of the same category [14][15] - The company must hold annual and extraordinary shareholder meetings, with specific procedures for calling and conducting these meetings [48][49] - Shareholder proposals must be submitted within a specified timeframe before meetings, ensuring transparency and participation [58][59]

董事离职管理制度 第一章 总则 第一条 为规范浙江海正药业股份有限公司（以下简称"公司"）董事离职程序， 确保公司治理结构的稳定性和连续性，维护公司及股东的合法权益，根据《中华人民 共和国公司法》《上市公司章程指引》《浙江海正药业股份有限公司章程》（以下简 称《公司章程》）等有关规定，结合公司实际情况，制定本制度。 第二条 本制度适用于公司全体董事（含独立董事）因任期届满、辞任、解任等 离职情形。 第二章 离职情形与程序 第三条 董事可以在任期届满以前辞任。董事辞任应当向公司提交书面辞职报告， 公司收到辞职报告之日辞任生效，公司将在两个交易日内披露有关情况。 浙江海正药业股份有限公司 涉及独立董事辞职的，需说明是否对公司治理及独立性构成重大影响。 董事提出辞职的，公司应当在60日内完成补选，确保董事会及其专门委员会构成 符合法律、行政法规和《公司章程》的规定。 第四条 如存在下列情形，在改选出的董事就任前，原董事仍应当依照法律、行 政法规、部门规章和《公司章程》的规定，履行董事职务，但存在相关法规另有规定 的除外： （一）董事辞职导致董事会成员低于法定最低人数； （二）审计委员会成员辞职导致审计委员会成员低于 ...